Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

Abstract Background Upon treatment with biopharmaceuticals, the immune system may produce anti-drug antibodies (ADA) that inhibit the therapy. Up to 40% of multiple sclerosis patients treated with interferon β (IFNβ) develop ADA, for which a genetic predisposition exists. Here, we present a genome-w...

Full description

Bibliographic Details
Main Authors: Till F. M. Andlauer, Jenny Link, Dorothea Martin, Malin Ryner, Christina Hermanrud, Verena Grummel, Michael Auer, Harald Hegen, Lilian Aly, Christiane Gasperi, Benjamin Knier, Bertram Müller-Myhsok, Poul Erik Hyldgaard Jensen, Finn Sellebjerg, Ingrid Kockum, Tomas Olsson, Marc Pallardy, Sebastian Spindeldreher, Florian Deisenhammer, Anna Fogdell-Hahn, Bernhard Hemmer, on behalf of the ABIRISK consortium
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Medicine
Subjects:
Multiple sclerosis
Interferon beta
Anti-drug antibodies
Human leukocyte antigen (HLA) system
Genetics
Genome-wide association study
Online Access:http://link.springer.com/article/10.1186/s12916-020-01769-6

Internet

http://link.springer.com/article/10.1186/s12916-020-01769-6

Similar Items